28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. 3 key findings →
Design: clinical trial Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
All patients taking donepezil completed the 30 days of treatment without adverse effects. 3 key findings →
Design: clinical trial Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Galantamine appears to be an effective and safe therapy for patients with DLB. 2 key findings →
Design: open-label trial Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Incorporating AD blood tests into screening for AD clinical trials may reduce the time and financial cost of enrollment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significantly increased levels of oxidized nucleic acids, proteins, and lipids have been described in the brains of subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI) as well as young adults with Down syndrome, compared to age-matched controls. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Key results included a 35% slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) and a 36% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Overall, the study with the same protocol is going as expected with no serious AE or any major protocol deviation. 2 key findings →
Participants: 150 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study will provide evidences to evaluate the efficacy and safety of SMYZD in combination with GBEs in treatment of VaD, as well as the adjuvant role of SMYZD in combination. 5 key findings →
Participants: 196 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Twelve cases of dementia were diagnosed among individuals with scores below cutoff point and one among subjects with high scores. 2 key findings →
Design: clinical trial Participants: 1,611 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Type 2 diabetes is associated with cognitive dysfunction and increases the risk of dementia in the elderly. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Chronic dialysis is associated with relatively high mortality and increased comorbidities that may render the patient unsuitable for renal transplantation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In amnestic mild cognitive impairment (aMCI), neuroinflammation evolves during disease progression, affecting microglial function and potentially accelerating the pathological process. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Multicomponent and transdisciplinary interventions focused on the family member–patient dyad have the potential to optimize cognitive outcomes and quality of life. 1 key finding →
Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The REMINDER program contributes to dementia prevention research by combining cognitive, lifestyle, and psychosocial strategies within a group-based format, aiming to foster long-term adherence to brain-protective behaviors. 4 key findings →
Participants: 270 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Previous data from familial AD due to mutations in presenilin 1 and presenilin 2 genes and the amyloid precursor protein suggest that the long form of Abeta peptide, Abeta42, is selectively increased in these circumstances. 3 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MCI represents a prodromal stage of AD, and inflammation occurs as one of the earliest pathological events in AD. 5 key findings →
Design: clinical trial Participants: 62 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The pathogenesis of HIV-associated cognitive changes is poorly understood. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive decline is an increasingly important public health problem, with more than 100 million adults worldwide projected to develop dementia by 2050. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The prevalence of dementia is expected to increase dramatically over the upcoming decades due to the aging population. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Administration of hUCB-MSCs into the hippocampus and precuneus by stereotactic injection was feasible, safe, and well tolerated. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
The decision-support intervention piloted in this study was feasible and relevant for surrogate decision-makers of persons with advanced dementia in NHs, and it improved quality of communication between SDM and NH providers. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
We systematically reviewed randomized clinical trials of problem-solving therapy (PST) in older adults. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Intranasal administration of ahaMSCs-Exos was safe and well tolerated, and a dose of at least 4×10 8 particles could be selected for further clinical trials. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common cause for dementia worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →